Aligos Therapeutics to Host Event on Positive Phase 1b Data for CHB Treatment

Aligos Therapeutics, Inc., a biopharmaceutical firm specializing in innovative treatments for liver and viral diseases, is set to host a virtual Key Opinion Leader (KOL) event. Scheduled for Thursday, July 18, 2024, at 3:00pm ET/12:00pm PT, the event will feature Dr. Mark Sulkowski from Johns Hopkins University School of Medicine. The focus will be on the current needs and treatment options for chronic hepatitis B (CHB) patients, along with insights into positive data from a Phase 1b study of the drug ALG-000184 and future development plans.

Dr. Mark Sulkowski, a prominent figure in the field, will offer his expert perspectives. He holds several key positions, including Professor of Medicine and the Senior Associate Dean for Clinical Trials at Johns Hopkins University School of Medicine. Additionally, he is the Founding Director of the Office of Clinical Trials, Director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center, Deputy Director for the Johns Hopkins Institute for Clinical and Translational Research, and Medical Director of the Viral Hepatitis Center.

Aligos Therapeutics has been encouraged by recent feedback from the FDA, allowing them to proceed with chronic HBV DNA suppression as a primary efficacy endpoint. Lawrence Blatt, Ph.D., MBA, Chairman, President, and CEO of Aligos, expressed enthusiasm about sharing this progress at the upcoming KOL event. According to Blatt, ALG-000184 monotherapy has demonstrated remarkable reductions in all viral markers of CHB without viral breakthrough, with data extending up to 72 weeks. During the EASL Congress 2024, these findings were presented, showcasing the drug's potential to outperform existing nucleos(t)ide analogs by reducing HBV DNA levels below 10 IU/mL in both HBeAg-positive and HBeAg-negative patients at Week 48.

Dr. Sulkowski's educational background includes an MD from Temple University School of Medicine, training in Internal Medicine at Duke University School of Medicine, and a Fellowship in Infectious Diseases at Johns Hopkins University School of Medicine.

The event aims to provide a comprehensive overview of the chronic suppression indication, the challenges faced by CHB patients, and the promising results from the Phase 1b study of ALG-000184. Attendees will gain valuable insights into the future development plans for ALG-000184 and the regulatory pathway for its approval.

Aligos Therapeutics, founded in 2018, aims to become a leader in treating liver and viral diseases. The company leverages its team's extensive expertise in drug development to create potentially groundbreaking therapeutics for conditions like metabolic dysfunction-associated steatohepatitis (MASH) and viral diseases such as hepatitis B and coronaviruses.